<html><head></head><body><h1>Ciclopirox Lotion</h1><p class="drug-subtitle"><b>Generic Name:</b> ciclopirox olamine<br/>
<b>Dosage Form:</b> topical lotion<br/></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Overview</li>
<li>Side Effects</li>
<li>Dosage</li>
<li>Professional</li>
<li>Pregnancy</li>
<li class="nav-more">
More&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewBox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/body&gt;&lt;/html&gt;
</li>
</ul><ul>
<li>Description</li>
<li>Clinical Pharmacology</li>
<li>Indications and Usage</li>
<li>Contraindications</li>
<li>Warnings</li>
<li>Precautions</li>
<li>Patient Counseling Information</li>
<li class="ddc-toggle-hidden">Adverse Reactions/Side Effects</li>
<li class="ddc-toggle-hidden">Dosage and Administration</li>
<li class="ddc-toggle-hidden">How Supplied/Storage and Handling</li>
</ul><p class="First"><span class="Bold">Rx only</span><br/>
<span class="Bold">FOR DERMATOLOGIC USE ONLY</span><br/>
<span class="Bold">NOT FOR OPHTHALMIC USE</span></p><h2>DESCRIPTION:</h2><p class="First">Ciclopirox Topical Suspension USP, 0.77% (Lotion) is for topical use.</p><p>Each gram of Ciclopirox Topical Suspension USP, 0.77% (Lotion) contains 7.7 mg of ciclopirox (as ciclopirox olamine) in a water miscible lotion base consisting of purified water USP, cocamide DEA, octyldodecanol NF, mineral oil USP, stearyl alcohol NF, cetyl alcohol NF, polysorbate 60 NF, myristyl alcohol NF, sorbitan monostearate NF, lactic acid USP, and benzyl alcohol NF (1%) as a preservative.</p><p>Ciclopirox Topical Suspension USP, 0.77% (Lotion) contains a synthetic, broad-spectrum, antifungal agent ciclopirox (as ciclopirox olamine). The chemical name is 6-cyclohexyl-1-hydroxy-4-methyl-2(1<span class="Italics">H</span>)-pyridone, 2-aminoethanol salt.</p><p>The CAS Registry Number is 41621-49-2. The chemical structure is:</p><p>Ciclopirox Topical Suspension USP, 0.77% (Lotion) has a pH of 7.</p><h2>CLINICAL PHARMACOLOGY:</h2><p class="First">Ciclopirox is a broad-spectrum, antifungal agent that inhibits the growth of pathogenic dermatophytes, yeasts, and <span class="Italics">Malassezia</span> <span class="Italics">furfur</span>. Ciclopirox exhibits fungicidal activity <span class="Italics">in vitro</span> against isolates of <span class="Italics">Trichophyton</span><span class="Italics"> </span><span class="Italics">rubrum</span><span class="Italics">,</span> <span class="Italics">Trichophyton</span><span class="Italics"> </span><span class="Italics">mentagrophytes</span><span class="Italics">,</span> <span class="Italics">Epidermophyton</span><span class="Italics"> </span><span class="Italics">floccosum</span><span class="Italics">,</span> <span class="Italics">Microsporum</span><span class="Italics"> </span><span class="Italics">canis</span><span class="Italics">,</span> and <span class="Italics">Candida</span> <span class="Italics">albicans</span>.</p><p>Pharmacokinetic studies in men with radiolabeled ciclopirox solution in polyethylene glycol 400, showed an average of 1.3% absorption of the dose when it was applied topically to 750 cm<span class="Sup">2</span> on the back followed by occlusion for 6 hours. The biological half-life was 1.7 hours and excretion occurred via the kidney. Two days after application only 0.01% of the dose applied could be found in the urine. Fecal excretion was negligible. Autoradiographic studies with human cadaver skin showed that ciclopirox penetrates into the hair and through the epidermis and hair follicles into the sebaceous glands and dermis, while a portion of the drug remains in the stratum corneum.</p><p><span class="Italics">In vitro</span> penetration studies in frozen or fresh excised human cadaver and pig skin indicated that the penetration of Ciclopirox Topical Suspension USP, 0.77% (Lotion) is equivalent to that of Ciclopirox Cream 0.77%. Therapeutic equivalence of cream and lotion formulations also was indicated by studies of experimentally induced guinea pig and human trichophytosis.</p><h2>INDICATIONS AND USAGE:</h2><p class="First">Ciclopirox Topical Suspension USP, 0.77% (Lotion) is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to <span class="Italics">Trichophyton</span><span class="Italics"> </span><span class="Italics">rubrum</span><span class="Italics">,</span> <span class="Italics">Trichophyton</span><span class="Italics"> </span><span class="Italics">mentagrophytes</span><span class="Italics">,</span> <span class="Italics">Epidermophyton</span><span class="Italics"> </span><span class="Italics">floccosum</span>, and <span class="Italics">Microsporum</span><span class="Italics"> </span><span class="Italics">canis</span>; cutaneous candidiasis (moniliasis) due to <span class="Italics">Candida</span> <span class="Italics">albicans</span>; and tinea (pityriasis) versicolor due to <span class="Italics">Malassezia</span> <span class="Italics">furfur</span>.</p><h2>CONTRAINDICATIONS:</h2><p class="First">Ciclopirox Topical Suspension USP, 0.77% (Lotion) is contraindicated in individuals who have shown hypersensitivity to any of its components.</p><h2>WARNINGS:</h2><p class="First"><span class="Bold"><span class="Bold">General</span></span>: Ciclopirox Topical Suspension USP, 0.77% (Lotion) is not for ophthalmic use.</p><p><span class="Bold">Keep out of reach of children.</span></p><h2>PRECAUTIONS:</h2><p class="First">If a reaction suggesting sensitivity or chemical irritation should occur with the use of Ciclopirox Topical Suspension USP, 0.77% (Lotion), treatment should be discontinued and appropriate therapy instituted.</p><h3>Information for Patients</h3><p class="First">The patient should be told to:</p><p class="First"><span class="Bold"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span></span> A carcinogenicity study in female mice dosed cutaneously twice per week for 50 weeks followed by a 6-month drug free observation period prior to necropsy revealed no evidence of tumors at the application site. The following <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> genotoxicity tests have been conducted with ciclopirox olamine: studies to evaluate gene mutation in the Ames <span class="Italics">Salmonella I</span> Mammalian Microsome Assay (negative) and Yeast Saccharomyces Cerevisiae Assay (negative); and studies to evaluate chromosome aberrations <span class="Italics">in vivo</span> in the Mouse Dominant Lethal Assay, and in the Mouse Micronucleus Assay at 500 mg/kg (negative). The following battery of <span class="Italics">in vitro</span> genotoxicity tests were conducted with ciclopirox: a chromosome aberration assay in V79 Chinese Hamster Cells, with and without metabolic activation (positive); a gene mutation assay in the HGPRT - test with V79 Chinese Hamster Cells (negative); and a primary DNA damage assay (i.e., unscheduled DNA Synthesis Assay in A549 Human Cells (negative)). An <span class="Italics">in vitro</span> Cell Transformation Assay in BALB/C3T3 Cells was negative for cell transformation. In an <span class="Italics">in vivo</span> Chinese Hamster Bone Marrow Cytogenetic Assay, ciclopirox was negative for chromosome aberrations at 5000 mg/kg.</p><p class="First"><span class="Bold"><span class="Bold">Pregnancy Category B</span></span>. Reproduction studies have been performed in the mouse, rat, rabbit, and monkey, via various routes of administration, at doses 10 times or more the topical human dose and have revealed no significant evidence of impaired fertility or harm to the fetus due to ciclopirox. There are, however, no adequate or well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p><p class="First"><span class="Bold"><span class="Bold">Nursing Mothers:</span></span> It is not known whether this drug is excreted in human milk. Caution should be exercised when Ciclopirox Topical Suspension USP, 0.77% (Lotion) is administered to a nursing woman.</p><p class="First"><span class="Bold"><span class="Bold">Pediatric Use:</span></span> Safety and effectiveness in pediatric patients below the age of 10 years have not been established.</p><h2>ADVERSE REACTIONS:</h2><p class="First">In the controlled clinical trial with 89 patients using Ciclopirox Topical Suspension USP, 0.77% (Lotion) and 89 patients using the lotion vehicle, the incidence of adverse reactions was low. Those considered possibly related to treatment or occurring in more than one patient were pruritus, which occurred in two patients using Ciclopirox Topical Suspension USP, 0.77% (Lotion) and one patient using the lotion vehicle; and burning, which occurred in one patient using Ciclopirox Topical Suspension USP, 0.77% (Lotion).</p><h2>DOSAGE AND ADMINISTRATION:</h2><p class="First">Gently massage Ciclopirox Topical Suspension USP, 0.77% (Lotion) into the affected and surrounding skin areas twice daily, in the morning and evening. Clinical improvement with relief of pruritus and other symptoms usually occurs within the first week of treatment. If a patient shows no clinical improvement after four weeks of treatment with Ciclopirox Topical Suspension USP, 0.77% (Lotion) the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.</p><h2>HOW SUPPLIED:</h2><p class="First">Ciclopirox Topical Suspension USP, 0.77% (Lotion) is supplied in:</p><p><span class="Bold">Bottle space provided to allow for vigorous shaking before each use.</span><br/>
Store between 5°-25°C (41°-77°F).</p><p><span class="Bold">E. FOUGERA &amp; CO</span>.<br/>
A division of<br/>
<span class="Bold">Fougera</span><br/>
PHARMACEUTICAL INC.<br/>
Melville, New York 11747</p><p>I2314C/IF2314C<br/>
R08/14<br/>
#218</p><h2>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 30 ML CONTAINER</h2><p class="First"><span class="Bold">NDC</span> 0168-0314-30</p><p><span class="Bold">Fougera</span><span class="Bold"><span class="Sup">®</span></span></p><p><span class="Bold">CICLOPIROX</span><br/>
<span class="Bold">TOPICAL</span><br/>
<span class="Bold">SUSPENSION</span><br/>
<span class="Bold">USP 0.77</span><span class="Bold">%</span><br/>
<span class="Bold">(w/w) (LOTION)</span></p><p><span class="Bold">Rx Only</span></p><p>FOR DERMATOLOGIC USE ONLY<br/>
NOT FOR OPHTHALMIC USE</p><p><span class="Bold">Keep out of reach of children.</span><br/>
<span class="Bold">Bottle space provided to allow for</span><br/>
<span class="Bold">vigorous shaking before each use.</span></p><p><span class="Bold">30 mL</span></p><h2>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 30 ML CARTON</h2><p class="First"><span class="Bold">NDC</span> 0168-0314-30</p><p><span class="Bold">Fougera</span><span class="Bold"><span class="Sup">®</span></span></p><p><span class="Bold">CICLOPIROX</span><br/>
<span class="Bold">TOPICAL</span><br/>
<span class="Bold">SUSPENSION</span><span class="Bold">,</span><br/>
<span class="Bold">USP 0.77%</span><br/>
<span class="Bold">(w/w) (LOTION)</span></p><p><span class="Bold">Rx Only</span></p><p>FOR DERMATOLOGIC<br/>
USE ONLY<br/>
NOT FOR OPHTHALMIC USE</p><p><span class="Bold">Keep out of reach</span><br/>
<span class="Bold">of children.</span></p><p><span class="Bold">Bottle space provided to</span><br/>
<span class="Bold">allow for vigorous shaking</span><br/>
<span class="Bold">before each use.</span></p><p><span class="Bold">30 mL</span></p><h2>More about ciclopirox topical</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>48 Reviews</li>
<li>Drug class: topical antifungals</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ciclopirox Topical &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li>Ciclopirox &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Professional Patient Advice)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Ciclopirox &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Ciclopirox Gel &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Ciclopirox Nail Lacquer &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Onychomycosis, Toenail</li>
<li>Seborrheic Dermatitis</li>
<li>Cutaneous Candidiasis</li>
<li>Onychomycosis, Fingernail</li>
<li data-more-config-id="list-data-resources-conditions">... +4 more</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>